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Abstract 
Barmumycin was isolated from an extract of the marine actinomycete Streptomyces sp. 
BOSC-022A and found to be cytotoxic against various human tumor cell lines. Based on 
preliminary one- and two-dimensional 1H- and 13C-NMR spectra, the natural compound was 
initially assigned the structure of macrolactone-type compound 1, which was later prepared by 
two different routes. However, major spectroscopic differences between isolated 
barmumycin and 1 led to revision of the proposed structure as E-16. Based on synthesis of 
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this new compound, and subsequent spectroscopic comparison of it to an authentic sample of 
barmumycin, the structure of the natural compound was indeed confirmed as that of E-16.  
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Introduction 
Natural products from terrestrial plants and microorganisms have long been a traditional 
source of drugs; however, over the past few years, marine organisms have garnered ever-
increasing attention as a rich bank of new bioactive compounds.1 Marine actinomycetes have 
also proven to be an important source of biologically active compounds.2  
Among the marine actinomycetes that our group has studied, those of the genus 
Streptomyces have clearly shown most pharmacological potential; however, in many bioactive 
cultures they have yielded only compounds that are already known. During ongoing research 
efforts to explore the biosynthetic potential of rare marine microorganisms, we isolated two 
known compounds pretomaymycin3 and oxotomaymycin4 (Figure 1) plus the previously 
unknown compound barmumycin from the culture broth of the marine actinomycete 
Streptomyces sp. BOSC-022A, isolated from a tunicate collected off the Scottish coast. 
Barmumycin and its diacetate show antitumor activity at micromolar concentrations in all 12 
cancer cell lines tested (see Table 1 in the Supporting Information). Herein we report the 
isolation, total synthesis and structure elucidation of barmumycin.  
 
Figure 1. The two known compounds isolated from Streptomyces sp. BOSC-022A  
 
Results and Discussion 
 The molecular formula of barmumycin was determined to be C15H19NO4, by HRMS 
MALDI-TOF, it gave an (M+H)+ ion at m/z 278.13840 (calcd. m/z 278.13869 for C15H20NO4). 
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Reaction of barmumycin with acetic anhydride and pyridine gave a diacetyl derivative, 
confirmed by MS, pointing the presence of two OH and/or NH protons (see Figure 2).  
1H-NMR shows three groups of protons (see Table 2 in the Supporting Information). 
The first group is in the aromatic region and contains three protons, at 6.90 (d), 7.03 (d) and 
7.08 (s) ppm; the chemical shifts indicated a 1,2,4-substituted electron-rich benzene ring. The 
second group corresponds to a single vinylic proton at 5.34 ppm (m). The third region 
comprises an upfield includes a CH shift at 4.67 ppm (m); two methyl groups, seen at 3.90 
ppm (s) and 1.62 ppm (d); and the signals of three CH2 at 4.07 (bt), 4.18 (bd), 3.75 (m), 2.29 
(m) and 2.71 (m) ppm. Based on these data, the MS findings, and further data from one-
dimensional and two-dimensional (COSY, HMBC and NOESY) 1H- and 13C-NMR 
experiments, we initially proposed that the structure of the isolated natural product was that of 
benzomacrolactone 1, derived from 5-methoxy-2-aminobenzoic acid with an exocyclic E-
ethylidene and one alcohol function (Figure 2).  
 
Figure 2. Structure of 1, showing 1H- NMR (blue) and 13C-NMR (red) chemical shifts 
(left); and its HMBC and NOE correlations (right). 
Decanolides are chemical entities abundant in terrestrial organisms, though only a few 
(e.g. modiolides A and B,5 and xestodecalactones A-C6) have been isolated from marine 
sources. To the best of our knowledge, the aniline moiety within its ten-membered lactone 
had never been reported in naturally occurring macrocycles. 
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We sought to synthesize 1 to compare it against an authentic sample of barmumycin in 
order to assess its structural assignment. Our retrosynthetic analysis of 1 entailed formation of 
the exocyclic double bond via Wittig reaction; dihydroxylation of a double bond to give the 
alcohol required for lactonization; and finally, introduction of a functionalized five-carbon 
chain onto the nitrogen of methyl 2-amino-5-methoxybenzoate (Scheme 1). 
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Scheme 1. Retrosynthetic analysis of compound 1. 
The functionalized five-carbon chain on the aniline nitrogen was introduced by two 
different ways: via reductive amination (Scheme 2) and via N-alkylation (Scheme 3). 
Homoallylic alcohol 2 was obtained by Barbier reaction of 2,2-dimethoxyacetaldehyde 
with allyl bromide and indium powder in water (95% yield).7  
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Scheme 2. Route A for the synthesis of 10. 
Attempts at direct deprotection of the dimethylacetal under acidic conditions led to 
polymerization of 2;8 therefore, the alcohol had to be protected. Acetylation of the alcohol to 
give compound 3,7 followed by dimethyl acetal deprotection using LiBF4 in MeCN-H2O,9 
gave the aldehyde 4 in excellent yield. Reductive amination of 4 with aniline 510 required 
special conditions due to the poor nucleophilicity of the aniline (which is deactivated by the 
methyl ester group in ortho position): thus, reaction of 4, 5, phenylsilane, and dibutyltin 
dichloride under microwave irradiation for short reaction times gave the aminoalkene 6a in 
67% yield.11,12 Attempts at protecting the aniline NH in 6a as a tBu carbamate failed due to its 
poor reactivity; therefore, 6a was treated with K2CO3 in MeOH to give the deacetylated  
derivative 6b. However, all attempts at oxidizing 6b to its ketone derivative resulted in 
decomposition of the starting material.13 Thus, the aniline had to be protected, but this was not 
possible in the presence of the unprotected alcohol. Exploiting the lack of reactivity of the 
aromatic amine towards Boc protection, and using standard conditions, 6b was converted into 
its tBu carbonate derivative 6c in 43% yield.14 The aniline group of 6c was then orthogonally 
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protected using (CF3CO)2O in pyridine to afford the trifluoroacetamide derivative 6d in 
quantitative yield. Treatment of 6d with 10% TFA in CH2Cl2 to remove the carbonate gave 
the free alcohol 6e in quantitative yield. Compound 6e was then oxidized with Dess Martin 
periodinate (DMP)15 to yield the ketone 7 in 93% yield. Slow addition of 7 to N-
methylmorpholine oxide (NMO) and a catalytic amount of OsO4 in acetone-H2O, to generate 
the corresponding diol 8 while preventing double bond isomerization gave 8 in good yield. 
Diol 8 was further protected by conversion into its 2,2-dimethyl-1,3-dioxolane derivative 9, 
using 2,2-dimethoxypropane plus pyridinium p-toluenesulfonate (PPTS) as catalyst 
(quantitative yield). Deprotection of the amine in 9 via mild basic hydrolysis gave the free 
amine 10 in 97% yield. 
A faster and better-yielding synthesis of 10 (Scheme 3) was done in parallel to the route 
described above. The first step was dihydroxylation of iso-butyl but-3-enoate. The 
introduction of the bromomethyl residue was planned for a later step. The oxidation 
conditions described above afforded iso-butyl 3,4-dihydroxybutanoate (11), which was then 
further protected as the 2,2-dimethyl-1,3-dioxolane derivative 12, in excellent overall yield 
for both steps. The key step, transformation of 12 into the bromoketone 13 using 
bromomethyllithium, gave 13 in 49% yield. N-Alkylation of 5 with 13 under microwave 
irradiation gave 10.  
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Scheme 3. Route B for the synthesis of 10. 
Wittig chemistry was employed to introduce the ethylidene chain. Reaction of 10 with 
the Wittig ylide derived from ethyltriphenylphosphonium bromide yielded 14 (43%) as a 
mixture of Z/E-diastereomers.16 
 Z/E-14 was transformed into 1 in three successive reactions: hydrolysis of the methyl 
ester; acetonide deprotection under acidic conditions; and macrocyclization. The acid Z-15 
was obtained by purification of the Z/E mixture of acids by semipreparative HPLC.17 
Racemic Z-1 was obtained in 35% yield by acetal deprotection followed by 
macrocyclisation using EDC·HCl and solid-supported DMAP in a 5 mM CH2Cl2 solution. 
The 1H-NMR spectrum of Z-1 showed two doublets for the CH3 linked to the double bond 
(1.42 ppm and 1.45 ppm) and two quadruplets for the vinylic proton (5.51 and 5.53 ppm).18 
These data could be explained by the presence of two highly populated conformations of Z-1 
at room temperature. Therefore, we studied peak coalescence by 1H-NMR run at different 
  9
temperatures. Spectra from the initial experiments, run up to 55 ºC in CDCl3 as solvent, 
exhibited this trend, but coalescence was not reached at this temperature limit. Finally, 
coalescence was almost reached in DMSO-d6 as solvent at 145 ºC (see Table 4 in the 
Supporting Information). Moreover, comparison of spectroscopic data for barmumycin with 
those for Z-1 revealed dramatic differences in the chemical shifts (see Tables 2 and 3 in the 
Supporting Information). This discrepancy, although the conflicting stereochemistry of the 
two compounds (Z-1 and E- barmumycin), led us to pursue a new structural assignment. 
Re-evaluation of all possible alternative structures led us to systematic elucidation of E-
16 as a novel structure for barmumycin (Figure 3). Interestingly, the very close structural 
resemblance of 16 to the pretomaymycin and oxotomaymycin isolated from the extract 
(Figure 1) suggests that all three molecules could derive from the same biogenetic pathway.  
 
Figure 3. Structure proposed for barmumycin upon re-evaluation of NMR data. 
 In order to confirm that the structure of barmumycin is actually that of E-16, we 
synthesized the latter and subsequently compared it to an authentic sample of the former. This 
began with selective silyl protection of the primary alcohol in the commercially available N-
Boc-trans-4-hydroxy-L-prolinol followed by oxidation of the secondary alcohol in the 
derivative 17, which afforded ketone 18 in 62% yield over two steps (Scheme 4). Wittig 
chemistry was again employed to introduce the ethylidene chain: reaction of 18 with the 
Wittig ylide derived from ethyltriphenylphosphonium bromide yielded 19 as a 9:1 mixture of 
Z/E-diastereomers. Z/E-19 was used directly without separation, as a single purification was 
planned for the final step of the synthesis. The TMS ether and the tert-butyl carbamate of Z/E-
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19 were deprotected with 10% TFA in CH2Cl2 to give the pyrrolidine derivative Z/E-20. 
Coupling of Z/E-20 to vanillic acid using (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and N,N-diisopropylethylamine (DIEA) gave a 9:1 mixture of 
Z/E-16 diastereomers. The configuration of the double bond was established by the NOESY 
correlations in Z/E-16 between 5CH2 (4.00−4.20 ppm) and the CH3 (1.60 ppm) (see NOESY 
correlations in the Supporting Information). 
  None of the Horner-Wadsworth-Emmons reactions tested (using the appropriate 
phosphonate and different bases19) gave the desired E-19. However, the Kocienski variant of 
the Julia–Lythgoe olefination20 afforded a 2:1 mixture of E/Z-19. This process entails 
nucleophilic addition of 5-(ethylsulfonyl)-1-phenyl-1H-tetrazole anion to the ketone followed 
by transposition and elimination to give the double bond.  Again, deprotection of the hydroxyl 
group and the amine group was obtained using 10% TFA in CH2Cl2, and coupling of E/Z-20 
to vanillic acid using PyBOP and DIEA gave a 2:1 mixture of E/Z-16. This mixture was 
purified by semipreparative HPLC to obtain E-16 as a single diastereomer. The configuration 
of the double bond was established by the NOESY correlations in E-16 between 5CH2 
(4.00−4.22 ppm) and the vinyl proton (5.30-5.38 ppm) (see NOESY correlations in the 
Supporting Information). 
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Scheme 4. Preparation of Z/E-16 staring from N-Boc-trans-4-hydroxy-L-prolinol. 
 
Comparison of spectroscopic data obtained for E-16 and barmumycin confirmed that 
the revised structure is indeed the structure of the natural product. 
In summary, the previously unreported marine compound barmumycin was isolated, 
and its chemical formula was determined via mass spectrometry. Based on preliminary NMR 
data, barmumycin was initially assigned the structure of compound 1. To confirm this 
assignment, compound 1 was synthesized following two different strategies starting from an 
ortho-aminobenzoic ester: one based on reductive amination, and one based on N-alkylation, 
which was shorter and higher-yielding. However, comparison of the NMR spectra for 1 with 
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those for isolated barmumycin showed dramatic differences. The structure of barmumycin 
was reassessed, and most probable option conceived was compound E-16, which was 
subsequently prepared (in five steps and 18% overall yield) for comparison with the natural 
compound. The spectroscopic data for E-16 fully coincided with that for barmumycin, 
thereby confirming that the two structures are equivalent. This work is a new example of the 
importance of total synthesis for structural characterization and confirmation of natural 
products21. 
 
Experimental section 
See Supporting Information for General Procedures. 
Extraction and isolation of barmumycin 
The culture broth (10 L) was separated by filtration into a mycelial cake and cultured filtrate (9 
L). A 500 mL aliquot of the absorber resin XAD-1180 was added to the filtrate. Compound 
barmumycin was eluted from the resin by double extraction with a 3:1:1 mixture of EtOAc-
MeOH-H2O (1.8 L). The active fractions were concentrated in the organic phase, which was 
concentrated to dryness in vacuo to yield 950 mg of crude extract. This extract purified by 
vacuum flash chromatography using a mixture of n-hexane-EtOAc and EtOAc-MeOH, whereby 
the fractions containing barmumycin (220 mg) were eluted with 9:1 EtOAc-MeOH. The active 
fractions were purified by silica gel chromatography using CHCl3-MeOH mixtures. Cytotoxicity 
was detected in the fractions eluted with 96:4 CHCl3-MeOH (20 mg). Further purification with a 
C18 column by HPLC afforded 6 mg of pure barmumycin (elution with 54:46 H2O/MeOH ). 
This quantity of barmumycin was treated with 0.5 mL of pyridine and 0.5 ml of Ac2O to afford 
7 mg of the corresponding diacetate. The molecular formula of barmumycin was determined 
to be C15H19NO4 by HPLC-APESI MS, in which it gave an (M+Na)+ peak at 300 and (M-H)- 
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276. Barmumycin gave an (M+H)+ peak at 278 and (M-H)- 276 in HPLC-APCI MS and it gave 
an (M+H)+ ion at m/z 278.13840 (calcd. m/z 278.13869 for C15H20NO4) in HRMALDI-TOF 
MS.  
The diacetyl derivative of barmumycin gave an (M+H)+ peak at 362 and an (M+Na)+ peak at 
384, by HPLC-APCI MS and HPLC-ESI MS. 
 
2-Acetoxypent-4-enal (4). LiBF4 (6.05 g, 64.5 mmol) was added to a solution of 3 (4.05 g, 
21.5 mmol) in 98:2 MeCN/H2O (110 mL) and the mixture was stirred for 72 h at room 
temperature. The solvents were removed in vacuo. The crude was dissolved in CH2Cl2, 
washed with water and brine, and then concentrated in vacuo to yield 4 (2.82 g, 92%) as a 
yellowish oil. IR (KBr film) ν 3080, 2932, 1744, 1373, 1237, 1048 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 2.18 (s, 3H); 2.32−2.65 (m, 2H); 5.06−5.30 (m, 3H); 5.65−5.87 (m, 1H); 9.54 (s, 
1H). 13C NMR (100.6 MHz, CDCl3) δ 20.4 (q); 33.1 (t); 77.2 (d); 119.0 (t); 131.4 (d); 170.4 
(s); 197.9 (d). MS (ESI-TOF) 143 (M+1, 100).  
Methyl 2-(2-acetoxypent-4-enylamino)-5-methoxybenzoate (6a). PhSiH3 (2.01 g, 18.6 
mmol) was added to a THF solution (12 mL) of 5 (2.02 g, 9.3 mmol), 4 (1.32 g, 9.3 mmol) 
and Bu2SnCl2 (282.3 mg, 0.9 mmol) in a sealed tube. The mixture was heated to 100 ºC under 
MW irradiation for 15 min. The solvents were removed in vacuo. Purification by silica gel 
column chromatography (100:0 to 95:5 hexane-Et2O) yielded 6a (1.93 g, 67%) as a yellowish 
oil. IR (KBr film) ν 3479, 3370, 2951, 1739, 1691, 1520, 1223, 1042 cm-1. 1H NMR (400 
MHz, CDCl3) δ 2.06 (s, 3H, Me); 2.41−2.46 (m, 2H); 3.35−3.37 (m, 2H); 3.76 (s, 3H, OMe); 
3.86 (s, 3H, OMe); 5.09-5.17 (m, 3H); 5.78 (ddt, J = 17.2, 10.1 and 7.1 Hz, 1H); 6.74 (d, J = 
9.2 Hz, 1H); 7.04 (dd, J = 9.2, 3.1 Hz, 1H); 7.42 (d, J = 3.1 Hz, 1H); 7.55 (bs, 1H, NH). 13C 
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NMR (100.6 MHz, CDCl3) δ 21.0 (q); 36.3 (t); 45.6 (t); 51.5 (q); 55.9 (q); 71.6 (d); 110.2 (s); 
112.9 (d); 114.3 (d); 118.3 (t); 123.3 (d); 133.0 (d); 146.0 (s); 149.5 (s); 168.6 (s); 170.6 (s). 
MS (ESI-TOF) 308 (M+1, 82). HRMS m/z calcd. for C16H22NO5 308.1498, found 308.1504. 
Methyl 2-(2-hydroxypent-4-enylamino)-5-methoxybenzoate (6b). K2CO3 (953.5 mg, 6.9 
mmol) was added to a solution of 6a (1.92 g, 6.27 mmol) in MeOH (75 mL). The mixture was 
stirred for 1 h at room temperature. The solvent was removed in vacuo. The residue was 
dissolved in CH2Cl2, and then washed with water and brine. The organic extracts were dried 
over MgSO4, and then concentrated in vacuo. Purification by silica gel column 
chromatography (85:15 to 75:25 hexane/EtOAc) yielded 6b (1.55 g, 93%) as a yellow oil. IR 
(KBr film) ν 3370, 1688, 1518, 1437, 1222, 1073 cm-1. 1H NMR (400 MHz, CDCl3) δ 2.27-
2.43 (m, 2H); 3.20 (dd, J = 13.0 and 7.7 Hz, 1H); 3.33 (dd, J = 13.0 and 4.5 Hz, 1H); 3.77 (s, 
3H, OMe); 3.87 (s, 3H, OMe); 3.96 (m, 1H); 5.17 (m, 1H); 5.19 (m, 1H); 5.87 (m, 1H); 6.75 
(d, J = 9.1 Hz, 1H); 7.04 (dd, J = 9.1, 3.1 Hz, 1H); 7.44 (d, J = 3.1 Hz, 1H). 13C NMR (100.6 
MHz, CDCl3) δ 39.5 (t); 49.3 (t); 51.7 (q); 56.0 (q); 69.3 (d); 110.8 (s); 113.6 (d); 114.5 (d); 
118.5 (t); 123.2 (d); 133.9 (d); 145.8 (s); 149.9 (s); 168.6 (s). MS (ESI-TOF) 266 (M+1, 100). 
HRMS m/z calcd. for C14H20NO4 266.1392, found 266.1398. 
Methyl 2-(2-(tert-butoxycarbonyloxy)pent-4-enylamino)-5-methoxybenzoate (6c). Boc2O 
(823 mg, 3.77 mmol) was added to a solution of 6b (909.4 mg, 3.43 mmol) and DMAP (125.6 
mg, 1.03 mmol) in dry CH2Cl2 (50 mL). The reaction mixture was stirred for 40 h at room 
temperature and then concentrated in vacuo. Purification by silica gel column 
chromatography (100:0 to 95:5 hexane-EtOAc) yielded 6c (543 mg, 43%) as a yellowish oil. 
IR (KBr film) ν 3369, 3078, 1730, 1709, 1500, 1368 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.47 
(s, 9H); 2.41−2.48 (m, 2H); 3.39 (d, J = 6.1 Hz, 2H); 3.76 (s, 3H, OMe); 3.85 (s, 3H, OMe); 
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4.91 (p, J = 6.1 Hz, 1H); 5.12 (m, 1H); 5.17 (m, 1H); 5.82 (m, 1H); 6.74 (d, J = 9.2 Hz, 1H); 
7.04 (dd, J = 9.2, 3.1 Hz, 1H); 7.42 (d, J = 3.1 Hz, 1H). 13C NMR (100.6 MHz, CDCl3) δ 27.7 
(q); 36.5 (t); 45.9 (t); 51.6 (q); 56.0 (q); 74.4 (d); 82.2 (s); 110.4 (s); 112.9 (d); 114.4 (d); 
118.4 (t); 123.3 (d); 132.9 (d); 145.8 (s); 149.6 (s); 153.2 (s); 168.5 (s). MS (ESI-TOF) 366 
(M+1, 100). HRMS m/z calcd. for C19H28NO6 366.1917, found 366.1917. 
Methyl 2-[N-(2-(tert-butoxycarbonyloxy)pent-4-enyl)-trifluoroacetamido]-5-
methoxybenzoate (6d). TFAA (0.3 mL, 2.2 mmol) was added to a cooled (0 ºC) solution of 
6c (542.9 mg, 1.49 mmol) in pyridine (20 mL) and the mixture was stirred at 0 ºC for 90 min. 
The crude was concentrated in vacuo, dissolved in CH2Cl2, and then washed with NH4Cl, 
water and brine. The organic extracts were dried over MgSO4, and then concentrated in vacuo 
to yield 6d, as a mixture of rotamers, (685 mg, quant.), as a yellowish oil. IR (KBr film) ν 
1736, 1707, 1502, 1282 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.42 and 1.47 (2s, 9H); 
2.32−2.40 (m, 2H, CH2); 3.04 and 3.31 (2dd, J = 14.4, 9.3 and 14.8, 2.2 Hz, 1H, CH2); 3.86 
(s, 3H, OMe); 3.87 (s, 3H, OMe); 4.41 and 4.51 (2dd, J = 14.4, 2.9 and 14.8, 8.9 Hz, 1H, 
CH2); 4.82−4.87 and 5.17−5.23 (2m, 1H, CH); 5.05−5.17 (m, 2H); 5.65−5.81 (m, 1H); 7.04 
and 7.10 (2dd, J = 8.8, 3.0 Hz, 1H); 7.24 and 7.51 (2d, J = 8.8 Hz, 1H); 7.55 and 7.57 (2d, J = 
3.0 Hz, 1H). 13C NMR (100.6 MHz, CDCl3) δ 27.6 and 27.7 (3q); 36.7 and 37.1 (t); 52.7 (q); 
54.0 and 55.8 (t); 55.7 (q); 73.3 and 73.7 (d); 82.3 (s); 116.4 and 116.8 (d); 118.5 and 118.7 
(d); 118.6 (t); 132.2 and 132.3 (d); 132.7 (d); 152.7 (s); 153.1 (s); 159.6 and 159.7 (s); 164.8 
and 164.9 (s); 171.1 (s). 19F NMR (376 MHz, CDCl3) δ -68.8 and -69.0 (2s). MS (ESI-TOF) 
945 (2M+Na, 15). HRMS m/z calcd. for C42H52N2O14F6Na 945.3220, found 945.3208. 
Methyl 5-methoxy-2-[N-(2-hydroxypent-4-enyl)trifluoroacetamido]benzoate (6e). A 10% 
solution of TFA in CH2Cl2 (50 mL) was added to 6d (494.9 mg, 1.07 mmol) and the mixture 
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was stirred at room temperature for 25 min. Elimination of the solvent gave 6e (387 mg, 
quant.) as a yellow oil. IR (KBr film) ν 3370, 2950, 1688, 1519, 1437, 1222, 1074 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 2.20−2.30 (m, 2H, CH2); 3.46−3.49 and 3.54−3.61 (m, 1H); 3.88 
(s, 3H, OMe); 3.90 (s, 3H, OMe); 4.02−4.15 (m, 2H); 4.89 (bs, 1H, OH); 5.10−5.14 (m, 2H); 
5.72−5.81 (m, 1H); 7.09−7.14 (m, 1H); 7.31 and 7.39 (2d, J = 8.8 Hz, 1H); 7.55 (d, J = 2.5 
Hz, 1H). 13C NMR (100.6 MHz, CDCl3) δ 39.3 and 39.4 (t); 52.9 (q); 55.8 (q); 58.4 and 59.0 
(t); 68.2 and 68.8 (d); 114.9 (s); 116.2 and 116.7 (d); 118.8 (t); 118.9 and 119.0 (d); 120.1 (s); 
120.9 (s); 122.8 (s); 131.1 (s); 131.9 and 132.1 (d); 133.1 and 133.4 (d); 159.8 (s). 19F NMR 
(376 MHz, CDCl3) δ −68.7 (s). MS (ESI-TOF) 362 (M+1, 37). HRMS m/z calcd. for 
C16H19NO5F3 362.1215, found 362.1211. 
Methyl 5-methoxy-2-[N-(2-oxopent-4-enyl)trifluoroacetamido]benzoate (7). Dess-Martin 
periodinane (606.4 mg, 1.43 mmol) was added to a solution of 6e (469.6 mg, 1.30 mmol) in 
anhydrous CH2Cl2 (35 mL). The mixture was stirred for 1 h, and then diluted with Et2O and 
hexane to a final concentration of 30:20:50 CH2Cl2/Et2O/hexane. The solution was filtered 
through a silica gel pad. The solvents were removed in vacuo to yield 7 (433 mg, 93%) as a 
yellowish oil. IR (KBr film) ν 1707, 1704, 1502, 1291, 1204, 1153 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 3.18 (dd, J = 16.8 and 6.7 Hz, 1H); 3.27 (dd, J = 16.8 and 7.2 Hz, 1H); 3.85 (m, 
1H); 3.86 (s, 3H, OMe); 3.89 (s, 3H, OMe); 5.13−5.23 (m, 3H); 5.95 (m, 1H); 7.06 (dd, J = 
8.8 and 3.0 Hz, 1H); 7.51 (d, J = 3.0 Hz, 1H); 7.59 (d, J = 8.8 Hz, 1H). 13C NMR (100.6 
MHz, CDCl3) δ 45.0 (t); 52.7 (q); 55.7 (q); 60.4 (t); 114.7 (s); 116.5 (d); 117.6 (s); 118.4 (d); 
119.9 (t); 129.0 (s); 129.1 (d); 131.6 (s); 132.6 (d); 159.8 (s); 165.0 (s); 200.8 (s). 19F NMR 
(376 MHz, CDCl3) δ -68.8 (s). MS (ESI-TOF) 360 (M+1, 100). HRMS m/z calcd. for 
C16H17NO5F3 360.1059, found 360.1072. 
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Methyl 5-methoxy-2-[N-(2,4,5-trihydroxypent-2-enyl)trifluoroacetamido]benzoate (8). A 
solution of 7 (775 mg, 2.16 mmol) in acetone (20 mL) was added dropwise over 10 h to a 
stirring solution of N-methylmorpholine oxide (337 mg, 2.37 mmol) and OsO4 (catalytic 
amount) in 60:40 acetone/H2O (64 mL). The mixture was stirred for 20 h at room temperature 
then quenched with 40% aq. NaHSO3 (3 mL) and subsequently concentrated in vacuo. The 
residue was dissolved in EtOAc, dried over MgSO4, filtered, and then re-concentrated in 
vacuo. Purification by silica gel column chromatography (100:0 to 90:10 CH2Cl2-MeOH) 
yielded 8 (628 mg, 84%) as a brownish oil. IR (KBr film) ν 1725, 1605, 1503, 1293, 1204 cm-
1
. 
1H NMR (400 MHz, DMSO-d6) δ 3.25−3.30 (m, 1H); 3.36−3.43 (m, 1H); 3.63−3.71 (m, 
1H, CH); 3.84 (s, 6H, 2OMe); 4.12−4.13 (m, 1H); 4.16 and 4.33 (2d, J = 18.5 Hz, 1H); 5.14 
and 5.33 (2d, J = 18.5 Hz, 1H); 7.27 and 7.29 (2dd, J = 3.0 Hz, 1H); 7.41−7.48 (m, 2H). 13C 
NMR (100.6 MHz, DMSO-d6) δ 52.6 (q); 55.7 (q); 59.4 and 60.2 (t); 61.3 (t); 72.2 and 72.9 
(d); 76.0 and 76.1 (d); 116.0 (d); 118.5 (d); 128.6 (s); 128.7 (s); 131.2 (s); 131.9 (d); 159.2 (s); 
164.4 (s); 206.2 (s); 207.5 (s). 19F NMR (376 MHz, CDCl3) δ -68.8 (s). MS (ESI-TOF) 392 
(M-1, 100); 394 (M+1, 40). HRMS m/z calcd. for C16H17NO7F3 392.0957, found 392.0946. 
Methyl 2-[N-(3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-oxopropyl)trifluoroacetamido]-5-
methoxybenzoate (9). Pyridinium p-toluenesulfonate (18.7 mg, 74 mmol) was added to a 
solution of 8 (584 mg, 1.49 mol) and 2,2-dimethoxypropane (1.82 mL, 14.8 mmol) in CH2Cl2 
(30 mL). The mixture was stirred at 40 ºC for 16 h and then concentrated in vacuo. 
Purification by silica gel column chromatography (90:10 to 40:60 hexane-EtOAc) yielded 9 
(642 mg, quant.) as a yellowish oil. IR (KBr film) ν 1775, 1730, 1381, 1172, 1087, 1047 cm-1. 
1H NMR (400 MHz, CDCl3) δ 1.30 and 1.36 (2s, 6H); 2.59 and 2.69 (2dd, J = 16.3, 6.8 and 
16.7, 6.0 Hz, 1H, CH2); 2.81 and 2.90 (2dd, J = 16.7, 6.8 and 16.3, 6.0 Hz, 1H, CH2); 3.54 
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and 3.60 (2dd, J = 8.4, 6.6 Hz, 1H); 3.77−3.83 (m, 1H); 3.85 (s, 3H, OMe); 3.87 (s, 3H, 
OMe); 4.12−4.18 (m, 1H); 4.40−4.48 (m, 1H); 5.08 (d, J = 17.9 Hz, 1H); 5.13 (d, J = 17.9 Hz, 
1H); 7.048 and 7.051 (2dd, J = 8.8 and 3.0 Hz, 1H); 7.50 (d, J = 3.0 Hz, 1H); 7.55 and 7.57 
(2d, J = 8.8 Hz, 1H). 13C NMR (100.6 MHz, CDCl3) δ 25.4 (q); 26.8 (q); 44.3 and 44.4 (t); 
52.6 (q); 55.7 (q); 61.2 and 61.4 (t); 69.0 and 69.2 (t); 71.3 (d); 109.1 (s); 114.6 (s); 116.4 and 
116.5 (d); 117.5 (s); 118.4 (d); 129.0 (s); 131.6 (s); 132.5 and 132.6 (d); 159.8 (s); 164.9 (s); 
200.8 (s). 19F NMR (376 MHz, CDCl3) δ -68.8 (s). MS (ESI-TOF) 434 (M+1, 100).  
Isobutyl 3,4-dihydroxybutanoate (11). A solution of isobutyl but-3-enoate (10.5 g, 73.6 
mmol) in acetone (50 mL) was added dropwise over 20 h to a solution of N-
methylmorpholine oxide (10.9 g, 80.9 mmol) and a catalytic amount OsO4 in 60:40 
acetone/H2O (250 mL). The reaction was quenched with NaHSO3 40% aq. sol. (3 mL) and 
concentrated in vacuo. The crude was dissolved in EtOAc, filtered through silica gel and the 
eluent was concentrated in vacuo to yield 11 (12.6 g, 97%) as a yellow oil. IR (KBr film) ν 
3402, 2962, 1729, 1470, 1381, 1170, 1043 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.94 (d, J = 
6.8 Hz, 6H); 2.00–1.89 (m, 1H); 2.51 (dd, J = 16.4 and 4.0 Hz, 1H, CH2); 2.58 (dd, J = 16.4 
and 8.4 Hz, 1H, CH2); 3.58 (dd, J = 11.2 and 6.4 Hz, 1H, CH2); 3.69 (dd, J = 11.2 and 3.6 Hz, 
1H, CH2); 3.91 (d, J = 6.8 Hz, 2H); 4.10–4.18 (m, 1H). 13C NMR (100.6 MHz, CDCl3) δ 19.2 
(2q); 27.8 (d); 37.9 (t); 65.9 (t); 68.8 (d); 71.2 (t); 172.8 (s). MS (ESI-TOF) 177 (M+1, 45); 
199 (M+Na, 100). HRMS (+ESI): m/z calcd. for C8H17O4 (M+1) 177.1127, found 177.1127. 
calcd. for C8H16O4Na (M+Na) 199.0946, found 199.0945.  
Isobutyl 2,2-dimethyl-1,3-dioxolan-4-yl acetate (12). Pyridinium p-toluenesulfonate (120 
mg, 0.48 mmol) was added to a solution of 11 (15.4 g, 87.26 mmol) in 50:50 2,2-
dimethoxypropane/CH2Cl2 (300 mL). The reaction mixture was stirred at room temperature 
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for 16 h and then the solvent was removed in vacuo. Purification by silica gel column 
chromatography (50:50 hexane-EtOAc) yielded 12 (17.4 g, 92%) as a yellowish oil. IR (KBr 
film) ν 1736, 1380, 1370 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.93 (d, J = 6.8 Hz, 6H); 1.35 
(s, 3H); 1.41 (s, 3H); 1.98–1.87 (m, 1H); 2.52 (dd, J = 15.7 and 7.6 Hz, 1H, CH2); 2.72 (dd, J 
= 15.7 and 6.4 Hz, 1H, CH2); 3.65 (dd, J = 8.4 and 6.4 Hz, 1H, CH2); 3.88 (d, J = 6.4 Hz, 
2H); 4.16 (dd, J = 8.4 and 6.0 Hz, 1H, CH2); 4.40–4.51 (m, 1H). 13C NMR (100.6 MHz, 
CDCl3) δ 19.0 (2q); 25.5 (q); 26.9 (q); 27.6 (d); 39.0 (t); 69.2 (t); 70.8 (t); 72.1 (d); 109.1 (s); 
170.6 (s). 
1-Bromo-3-(2,2-dimethyl-1,3-dioxolan-4-yl)propan-2-one (13). A 1.6 M solution of MeLi 
in Et2O (5 mL, 8 mmol) was added to a solution of 12 (865 mg, 4 mmol) and 
dibromomethane (557 µL, 8 mmol) in THF (20 mL) at -116 ºC. The solution was stirred for 3 
h and then quenched with sat. NH4Cl (60 ml). The residue was immediately extracted with 
CH2Cl2. The organic layers were dried over MgSO4, filtered, and then concentrated in vacuo. 
Purification by silica gel column chromatography (80:20 to 70:30 hexane-EtOAc) yielded 13 
(460 mg, 49%) as a yellow oil. IR (KBr film) ν 1719, 1370, 840 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 1.35 (s, 3H); 1.42 (s, 3H); 2.82 (dd, J = 16.6 and 6.0 Hz, 1H, CH2); 3.07 (dd, J = 
16.6 and 6.8 Hz, 1H, CH2); 3.60 (dd, J = 8.4 and 6.4 Hz, 1H, CH2); 3.94 (s, 2H); 4.18 (dd, J = 
8.4 and 6.0 Hz, 1H, CH2); 4.44–4.51 (m, 1H). 13C NMR (100.6 MHz, CDCl3) δ 25.4 (q); 26.8 
(q); 34.6 (t); 44.16 (t); 69.2 (t); 71.8 (d); 109.3 (s); 199.7 (s). MS (ESI-TOF) 259 (MBr79+Na, 
100); 261 (MBr81+Na, 98). HRMS (+ESI): m/z calcd. for C8H13O3NaBr (M+Na) 258.9944, 
found 258.9946. 
Methyl 2-[3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-oxopropylamino]-5-methoxybenzoate 
(10): Route A. K2CO3 (68 mg, 0.5 mmol) was added to a solution of 9 (50 mg, 0.11 mmol) in 
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MeOH and the mixture was stirred for 1 h. The solvent was removed in vacuo and the 
resulting residue was purified by silica gel column chromatography  (95:5 to 80:20 
hexane/EtOAc) to yield 10 (38 mg, 97%) as a yellowish oil. 
Route B. 2,6-Lutidine (1.6 mL, 13.74 mmol) and tetrabutylammonium iodide (3.08 g, 8.33 
mmol) were added to a solution of 5 (1.21 g, 6.66 mmol) and 13 (1.37 g, 5.76 mmol) in 1,4-
dioxane (12 mL). The reaction mixture was stirred at 40 ºC for 15 min under microwave 
irradiation. Purification by silica gel column chromatography (95:5 to 80:20 hexane-EtOAc) 
yielded 10 (1.44 g, 74%) as a yellow oil. IR (KBr film) ν 3350, 1705, 1692, 1521, 1286, 
1225, 1045 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.34 (s, 3H); 1.40 (s, 3H); 2.64 (dd, J = 16.2, 
6.5 Hz, 1H, CH2); 2.94 (dd, J = 16.2, 6.5 Hz, 1H, CH2); 3.58 (dd, J = 8.4, 6.7 Hz, 1H); 3.76 
(s, 3H, OMe); 3.89 (s, 3H, OMe); 4.08 (bd, 2H, CH2); 4.18 (dd, J = 8.4 and 6.0 Hz, 1H); 4.46-
4.52 (m, 1H); 6.46 (d, J = 9.1 Hz, 1H); 7.02 (dd, J = 9.1 and 3.1 Hz, 1H); 7.45 (d, J = 3.1 Hz, 
1H); 7.99 (bt, 1H, NH). 13C NMR (100.6 MHz, CDCl3) δ 25.4 (q); 26.8 (q); 44.2 (t); 51.7 (q); 
54.2 (t); 55.9 (q); 69.3 (t); 71.8 (d); 109.1 (s); 110.8 (s); 112.7 (d); 114.8 (d); 123.1 (d); 144.7 
(s); 149.9 (s); 168.4 (s); 204.7 (s). MS (ESI-TOF) 338 (M+1, 47); 675 (2M+1, 100). HRMS 
m/z calcd. for C17H24NO6 338.1598, found 338.1603.  
(Z/E)-Methyl 2-[2-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)but-2-enylamino]-5-
methoxybenzoate (Z/E-14). A 2.5 M solution of BuLi in hexane (1.27 mL, 3.17 mmol) was 
added to a mixture of ethyltriphenylphosphonium bromide (1.18 g, 3.17 mmol) in anhydrous 
THF (13 mL). The reaction mixture was stirred at room temperature for 1 h and then cooled 
to -78 ºC. A solution of 10 (337 mg, 1.58 mmol) in anhydrous THF (3 mL) was added 
dropwise to the reaction mixture. The reaction mixture was stirred at -78 ºC for 30 min and 
subsequently allowed to warm to room temperature for an additional 30 min. The solvent was 
removed in vacuo and the residue was purified by silica gel column chromatography with 
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hexane-EtOAc (95:5 to 80:20) to yield Z-14 and E-14 as a yellowish oil (239 mg, 43%; 73:27 
Z/E, as determined by 1H NMR). IR (KBr film) ν 3373, 1689, 1517, 1222, 1065 cm-1. Z-14: 
1H NMR (400 MHz, CDCl3) δ 1.33 (s, 3H); 1.40 (s, 3H); 1.74 (d, J = 6.9 Hz, 3H); 2.23−2.44 
(m, 2H, CH2); 3.53 (dd, J = 7.8 and 7.4 Hz, 1H); 3.76 (s, 3H, OMe); 3.82 (bs, 2H, CH2); 3.85 
(s, 3H, OMe); 4.00 (dd, J = 7.8 and 6.0 Hz, 1H); 4.19−4.26 (m, 1H); 5.56 (q, J = 6.9 Hz, 1H); 
6.63 (d, J = 9.2 Hz, 1H); 7.03 (dd, J = 9.2 and 3.2 Hz, 1H); 7.42 (d, J = 3.2 Hz, 1H). E-14: 1H 
NMR (100.6 MHz, CDCl3) δ 1.35 (s, 3H); 1.43 (s, 3H); 1.65 (d, J = 6.9 Hz, 3H); 2.23−2.44 
(m, 2H, CH2); 3.56 (dd, J = 7.6 and 7.6 Hz, 1H); 3.75 (s, 3H, OMe); 3.82 (bs, 2H, CH2); 3.86 
(s, 3H, OMe); 4.02−4.05 (m, 1H); 4.19−4.26 (m, 1H); 5.62 (q, J = 6.9 Hz, 1H); 6.63 (d, J = 
9.2 Hz, 1H); 7.00 (dd, J = 9.2 and 3.1 Hz, 1H); 7.41 (d, J = 3.1 Hz, 1H). 13C NMR (400 MHz, 
CDCl3) δ 13.4 (q); 25.7 (q); 27.0 (q); 32.6 and 42.8 (t); 40.0 (t); 51.5 (q); 56.0 (q); 69.3 (t); 
75.0 (d); 108.9 (s); 112.8 and 114.1 (d); 114.4 (d); 123.3 (d); 125.4 (d); 133.0 (s); 133.7 (s); 
146.4 (s); 149.4 (s); 168.6 (s). MS (ESI-TOF) 350 (M+1, 35); 372 (M+Na, 45); 721 (2M+Na, 
100). HRMS m/z calcd. for C19H28NO5 350.1962, found 350.1961. 
(Z)-2-[2-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)but-2-enylamino]-5-methoxybenzoic 
acid (Z-15). LiOH (310 mg, 7.39 mmol) was added to a solution of Z/E-14 (258 mg, 0.74 
mmol) in 75:25 H2O/THF (20 mL). The reaction mixture was sonicated at room temperature 
for 1 h and then stirred at 50 ºC for 24 h. The crude mixture was washed with Et2O. The 
aqueous phase was cooled to 0 ºC, acidified to pH 7 with 4 M HCl (1.7 mL) and extracted 
with CH2Cl2. The combined organic extracts were dried over MgSO4, and then concentrated 
in vacuo to yield Z/E-15 (250 mg, quant.; 73:27 Z/E, as determined by 1H NMR) as a 
yellowish oil. Purification by semipreparative HPLC performed on a 15.5 g Redisep Gold C18 
(20-40 µm) column, with UV detection at 254 nm, a flow rate of 18 mL/min, and H2O-
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CH3CN as eluents (gradient: 80:20 to 60:40 in 50 min), yielded Z-15 (80 mg, 72% recovery). 
IR (KBr film) ν 3375, 2985, 1668, 1577, 1516, 1371, 1216, 1041 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 1.34 (s, 3H); 1.42 (s, 3H); 1.74 (d, J = 6.9 Hz, 3H); 2.27 (dd, J = 14.3 and 5.7 Hz, 
1H, CH2); 2.41 (dd, J = 14.3 and 7.1 Hz, 1H, CH2); 3.55 (t, J = 8.0 Hz, 1H); 3.78 (s, 3H, 
OMe); 3.86 (bs, 2H); 4.02 (dd, J = 8.0 and 6.0 Hz, 1H); 4.20−4.27 (m, 1H); 5.58 (q, J = 6.9 
Hz, 1H); 6.69 (d, J = 9.1 Hz, 1H); 7.08 (dd, J = 9.1 and 3.1 Hz, 1H); 7.49 (d, J = 3.1 Hz, 1H). 
13C NMR (100.6 MHz, CDCl3) δ 13.5 (q); 25.7 (q); 27.0 (q); 39.8 (t); 43.3 (t); 56.0 (q); 69.2 
(t); 75.1 (d); 109.1 (s); 109.8 (s); 113.9 (d); 114.6 (d); 124.5 (d); 125.8 (d); 133.3 (s); 146.3 
(s); 150.0 (s); 172.5 (s). MS (ESI-TOF) 336 (M+1, 100); 337 (M+2, 23).  
(Z)-3-Ethylidene-5-hydroxy-10-methoxy-1,2,3,4,5,6-hexahydrobenzo[c][1,5]oxazecin-8-
one (1). Z-15 (30 mg, 0.09 mmol) was stirred with 4 M HCl (4 mL) for 30 min and then 
concentrated in vacuo to yield (Z)-2-(2-ethylidene-4,5-dihydroxypentylamino)-5-
methoxybenzoic acid hydrochloride. The resulting residue was used in the following step 
without further purification. A mixture of EDC·HCl (69 mg, 0.36 mmol), (Z)-2-[2-ethylidene-
4,5-dihydroxypentylamino]-5-methoxybenzoic acid hydrochloride, solid supported DMAP 
(18 mg, 0.09 mmol), and molecular sieves 4 Å (254 mg) in dry CH2Cl2 (20 mL) was stirred at 
room temperature for 3 h.  The crude mixture was filtered, treated with sat. NH4Cl, and then 
extracted with CH2Cl2. The combined organic extracts were dried over MgSO4 and then 
concentrated in vacuo. Purification by silica gel column chromatography (100:0 to 80:20 
CH2Cl2/MeOH) yielded Z-1 as a brownish oil (9 mg, 35%). IR (KBr film) ν 3397, 1640, 
1498, 1436, 1292, 1228, 1039 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.42 and 1.45 (2d, J = 6.9 
Hz, 3H); 2.09−2.20 (m, 2H, CH2); 3.44−3.51 and 3.59−3.69 (2m, 2H, CH2); 3.73 (s, 3H, 
OMe); 3.79−3.90 (m, 1H); 4.35 (dd, J = 14.3 and 6.1 Hz, 1H, CH2); 4.82 (dd, J = 14.3, 3.1 
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Hz, 1H, CH2); 5.51 and 5.53 (2q, J = 6.9 Hz, 1H); 6.72−6.76 (m, 2H); 6.92 (2d, J = 8.5, 1H). 
13C NMR (100.6 MHz, CDCl3) δ 13.4 (q); 38.2 and 38.9 (t); 46.9 and 47.1 (t); 55.5 (q); 66.2 
and 66.8 (t); 70.4 and 70.9 (d); 111.5 and 111.6 (d); 116.5 (d); 127.0 and 127.1 (d); 127.9 and 
128.4 (d); 130.2 and 130.5 (s); 130.7 (s); 136.1 and 136.2 (s); 158.9 (s); 169.1 and 169.2 (s). 
MS (ESI-TOF) 299 (M+Na, 13); 555 (2M+1, 100); 577 (2M+Na, 100). HRMS m/z calcd. for 
C30H38N2O8Na 577.2520, found 577.2521. 
(2S,4R)-1-tert-Butoxycarbonyl-4-hydroxy-2-(trimethylsilyloxymethyl)pyrrolidine (17).. 
TMSCl (0.65 mL, 4.85 mmol) was added to a solution of N-Boc-trans-4-hydroxy-L-prolinol 
(1.054 g, 4.85 mmol), Et3N (0.67 mL, 4.85 mmol), and DMAP (50 mg, 0.4 mmol) in CH2Cl2 
(25 mL). The reaction mixture was stirred at 0 ºC for 16 h. After this time the reaction mixture 
was washed with water, dried over MgSO4, filtered, and the solvent was removed under 
reduced pressure. Purification by silica gel column chromatography with hexane-EtOAc 
(70:30 to 50:50) yielded 17 (444 mg, 32%) as a colorless oil. IR (KBr film) ν 3434, 1692, 
1678, 1408, 1119 cm-1. 1H NMR (400 MHz, CD3OD) δ 0.12 and 0.13 (2s, 9H); 1.50 and 1.51 
(2s, 9H); 1.90−2.04 (m, 1H, CH2); 2.18 (dt, J = 17.2 and 5.8 Hz, 1H, CH2); 3.35−3.48 (m, 2H, 
CH2); 3.63 and 3.65 (2d, J = 10.2 Hz, 1H, CH2); 3.78 and 3.90 (2dd, J = 10.2 and 4.6 Hz, 1H, 
CH2); 3.94−4.02 (m, 1H, CH); 4.38−4.44 (m, 1H, CH). 13C NMR (100.6 MHz, CD3OD) δ 
−0.5 (q); 28.8 (q); 37.3 and 38.2 (t); 55.9 and 56.4 (t); 58.8 and 58.9 (d); 63.6 and 64.6 (t); 
70.1 and 70.6 (d) 80.8 and 81.1 (s); 155.3 (s). HRMS m/z calcd. for C13H28NO4Si 290.1782, 
found 290.1784. 
(S)-1-tert-Butoxycarbonyl-2-(trimethylsilyloxymethyl)pyrrolidin-4-one (18). DMP (369 
mg, 0.87 mmol) was added to a solution of 17 (228 mg, 0.78 mmol) in CH2Cl2 (10 mL) and 
the reaction mixture was stirred at room temperature for 15 min. After this time sat. NaHCO3 
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and sat. Na2S2O3 were added and the reaction mixture was stirred for additional 10 minutes. 
The residue was extracted with CH2Cl2, the combined organic extracts were dried over 
MgSO4, filtered, and the solvent was removed under reduced pressure. Purification by silica 
gel column chromatography with hexane-EtOAc (80:20) yielded 18 (182 mg, 82%) as a 
colorless oil. IR (KBr film) ν 1765, 1701, 1401, 1106 cm-1. 1H NMR (400 MHz, CD3OD) δ 
0.12 (s, 9H); 1.54 (s, 9H); 2.41 (d, J = 18.0 Hz, 1H, CH2); 2.77−2.93 (m, 1H, CH2); 3.57−3.68 
(m, 2H, CH2); 3.86 (d, J = 18.0 Hz, 1H, CH2); 3.99 (dd, J = 22.1, 10.0 Hz, 1H, CH2);  4.38 
and 4.40 (2bs, 1H, CH). 13C NMR (100.6 MHz, CD3OD) δ −0.9 (q); 28.7 (q); 41.1 and 41.7 
(t); 54.4 and 54.9 (t); 56.8 and 57.4 (d); 65.3 and 66.1 (t), 81.6 (s). HRMS m/z calcd. for 
C13H26NO4Si 288.1626, found 288.1628. 
(S,Z)-1-tert-Butoxycarbonyl-4-ethylidene-2-((trimethylsilyloxy)methyl)pyrrolidine (Z-
19). tBuOK (213 mg, 1.9 mmol) was added to a solution of ethyltriphenylphosphonium 
bromide (705 mg, 1.9 mmol) in THF (5 ml), the mixture was stirred for 1 h. After this time 18 
(180 mg, 0.62 mmol) was added and the mixture was stirred for additional 30 min. Water was 
added and the residue was extracted with Et2O, dried over MgSO4, filtered, and the solvent 
was removed under reduced pressure. Purification by silica gel column chromatography with 
hexane-EtOAc (95:5) yielded Z/E-19 (136 mg, 73 %) in portion 9:1 as a colorless oil. IR (KBr 
film) ν  1702, 1397, 1251, 1109 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.09 (s, 9H,); 1.48 (s, 
9H); 1.58 (d, J = 6.8 Hz, CH3); 2.45−2.54 (m, 1H, CH2); 2.56−2.67 (m, 1H, CH2); 3.20−3.45 
(m, 1H, CH2); 3.55−3.67 (m, 1H, CH2); 3.78−4.05 (m, 3H, CH + CH2); 5.32−5.40 (m, 1H, 
CH). 13C NMR (100.6 MHz, CDCl3) δ −0.5 (q); 14.5 (q); 28.5 (q); 34.0 and 34.5 (t); 47.5 (t) 
57.5 and 57.7 (d); 62.7 and 63.1 (t); 79.4 (s); 115.9 and 116.2 (d); 136.7 (s); 154.2 (s). HRMS 
m/z calcd. for C15H30NO3Si 300.1989, found 300.1990. 
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(S,Z)-4-Ethylidene-2-(hydroxymethyl)pyrrolidine (Z-20). A solution of Z/E-19 in portion 
9:1 (136 mg, 0.45 mmol) in 10% TFA in CH2Cl2 (5 mL) was stirred at room temperature for 1 
h. The solvent was removed under reduced pressure and the residue was purified by silica gel 
column chromatography with CH2Cl2-MeOH (98:2 to 90:10) to obtain Z/E-20 (105 mg) in 
portion 9:1 quantitative yield. IR (KBr film) ν 3380, 1677, 1435, 1135 cm-1. 1H NMR (400 
MHz, CDCl3) δ 1.60 (d, J = 8.0 Hz, 3H, CH3); 2.34−2.45 (m, 1H, CH2); 2.58−2.68 (m, 1H, 
CH2); 3.65−3.95 (m, 5H); 5.50−5.58 (m, 1H, =CH). 13C NMR (100.6 MHz, CDCl3) δ 14.7 
(q); 32.2 (t); 45.8 (t); 60.5 (t); 61.4 (d); 120.6 (d); 130.9 (s). HRMS m/z calcd. for C7H14NO 
128.1069, found 128.1070. 
(S,Z)-N-(4-Hydroxy-3-methoxybenzoyl)-4-ethylidene-2-(hydroxymethyl)pyrrolidine (Z-
16). PyBOP (135 mg, 0.26 mmol) was added to a solution of DIEA (0.1 mL, 0.55 mmol) and 
vanillic acid (44 mg, 0.26 mmol) in THF (5 mL), and the mixture was stirred for 10 min. 
Then, a solution of Z/E -20 in portion 9:1 (26 mg, 0.21 mmol) in THF was added and the 
mixture was stirred for 1 h. The solvent was removed under reduced pressure and the residue 
was disolved in EtOAc, washed with sat. NaHCO3, and sat. NH4Cl. Purification by silica gel 
column chromatography with EtOAc yielded Z-16 (45 mg, 73%) in portion 9:1 as a colorless 
oil. [α]D = − 21.5 (c 0.75, CH2Cl2). IR (KBr film) ν 3288, 1600, 1585, 1431, 1277, 1207 cm-1. 
1H NMR (400 MHz, CDCl3) δ 1.60 (bs, 3H, CH3); 2.27−2.40 (m, 1H, CH2); 2.66−2.78 (m, 
1H, CH2); 3.65−3.75 (m, 2H, CH2); 3.90 (s, 3H, OMe); 4.00−4.20 (m, 2H, CH2); 4.53−4.69 
(m, 1H, CH); 5.30−5.45 (m, 1H); 6.91 (d, J = 8.1 Hz, 1H); 7.05 (dd, J = 8.1 and 1.8 Hz, 1H); 
7.09 (d, J = 1.8 Hz, 1H). 13C NMR (100.6  MHz, CDCl3) δ 14.5 (q); 34.1 (t); 51.5 (t); 56.1 
(q); 59.9 (d); 66.4 (t); 110.4 (d); 114.0 (d); 117.7 (d); 120.7 (d); 128.0 (s); 134.4 (s); 146.6 (s); 
147.6 (s); 172.0 (s). HRMS m/z calcd. for C15H20NO4 278.1387, found 278.1387. 
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(S,E)-1-tert-Butoxycarbonyl-4-ethylidene-2-(trimethylsilyloxymethyl)pyrrolidine (E-19). 
A 2M solution of LDA in THF (0.25 mL, 0.5 mmol) was added to a solution of 5-
(ethylsulfonyl)-1-phenyl-1H-tetrazole (119 mg, 0.5 mmol) in THF (4 ml) at −78 ºC and the 
mixture was stirred for 10 min. After this time, 18 (116 mg, 0.4 mmol) was added and the 
mixture was stirred for additional 30 min. The reaction mixture was quenched with sat. 
NH4Cl and was extracted with CH2Cl2. The organic fractions were dried over MgSO4, filtered 
and the solvent was removed under reduced pressure. Purification by silica gel column 
chromatography with hexane-EtOAc (97:3) yielded Z/E-19 (58 mg, 50 %) in portion 1:2 as a 
colorless oil. IR (KBr film) ν 1702, 1397, 1251, 1109 cm-1. E diastereomer: 1H NMR (400 
MHz, CDCl3) δ 0.09 (s, 9H); 1.46 (s, 9H); 1.62 (d, J = 6.7 Hz, CH3); 2.41−2.52 (m, 1H, CH2); 
2.54−2.66 (m, 1H, CH2); 3.20−3.45 (m, 1H, CH2); 3.55−3.65 (m, 1H, CH2); 3.72−3.80 (m, 
1H, CH2); 3.87−4.05 (m, 2H); 5.32−5.42 (m, 1H, CH). E diastereomer: 13C NMR (100.6 
MHz, CDCl3) δ −0.5 (q); 14.4 (q); 28.5 (q); 29.8 and 30.4 (t); 50.8 and 51.4 (t); 57.5 and 57.7 
(d); 62.7 and 63.1 (t); 79.4 (s); 115.5 and 116.1 (d); 136.7 (s); 154.2 (s). HRMS m/z calcd. for 
C15H30NO3Si 300.1989, found 300.1990. 
(S,E)-4-Ethylidene-2-(hydroxymethyl)pyrrolidine (E-20). A solution of Z/E-19 in portion 
1:2 (95 mg, 0.31 mmol) in 10% TFA in CH2Cl2 (5 mL) was stirred at room temperature for 1 
h. The solvent was removed under reduced pressure and the residue was purified by silica gel 
column chromatography with CH2Cl2-MeOH (98:2 to 90:10) to obtain Z/E-20 in portion 1:2 
in quantitative yield. IR (KBr film) ν 3380, 1677, 1435, 1135 cm-1. E diastereomer: 1H NMR 
(400 MHz, CDCl3) δ 1.63 (d, J = 6.7 Hz, 3H, CH3); 2.21−2.30 (m, 1H, CH2); 2.58−2.68 (m, 
1H, CH2); 3.65−3.95 (m, 5H); 5.50−5.58 (m, 1H, CH). E diastereomer: 13C NMR (100.6  
MHz, CDCl3) δ 14.7 (q); 28.2 (t); 48.7 (t); 60.8 (t); 61.6 (d); 120.6 (d); 130.9 (s). E 
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diastereomer: 1H NMR (400 MHz, CD3OD) δ 1.68 (d, J = 6.9 Hz, 3H, CH3); 2.40 (dd, J = 
16.4 and 8.4 Hz, 1H, CH2); 2.75 (dd, J = 16.4 and 7.0 Hz, 1H, CH2); 3.60−3.98 (m, 5H); 
5.55−5.67 (m, 1H, CH). E diastereomer: 13C NMR (100.6  MHz, CD3OD) δ 14.8 (q); 29.1 (t); 
50.1 (t); 61.2 (t); 62.7 (d); 121.0 (d); 133.1 (s). HRMS m/z calcd. for C7H14NO 128.1069, 
found 128.1070. 
(S,E)-N-(4-Hydroxy-3-methoxybenzoyl)-4-ethylidene-2-(hydroxymethyl)pyrrolidine (E-
16). PyBOP (93 mg, 0.18 mmol) was added to a solution of DIEA (64 µL, 0.37 mmol) and 
vanillic acid (30 mg, 0.18 mmol) in THF (5 mL), and the mixture was stirred for 10 min. 
After this time  a solution of  Z/E-20 in portion 1:2 (19 mg, 0.15 mmol) in THF was added 
and the mixture was stirred at room temperature for 1 h. The solvent was removed under 
reduced pressure and the residue was disolved in EtOAc, washed with sat. NaHCO3, and sat. 
NH4Cl. Purification by silica gel column chromatography with EtOAc yielded Z/E-16 (25 mg, 
60%) in portion 1:2. Purification by semipreparative HPLC using a Waters XBridge C18 
column (10×100 mm, 5µm), UV detection at 254 nm, with a flow of 3 mL/min, and using 
H2O-CH3CN 18:82 as solvent system in isocratic conditions, yielded E-16 (5.7 mg). The 1H-
NMR and 13C-NMR are identical as described for the natural product in Table 2 in the 
Supporting information. [α]D = − 51.2 (c 0.25, CH2Cl2). IR (KBr film) ν 3288, 1600, 1585, 
1431, 1277, 1207 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.62 (d, J = 6.8, 3H, CH3); 2.20−2.35 
(m, 1H, CH2); 2.67−2.77 (m, 1H, CH2); 3.75 (bs, 2H, CH2); 3.90 (s, 3H, OMe); 4.00−4.22 (m, 
2H, CH2); 4.67 (bs, 1H, CH); 5.34 (bs, 1H, CH); 6.91 (d, J = 7.8 Hz, 1H, Ar); 7.04 (d, J = 7.8, 
1H, Ar); 7.09 (s, 1H, Ar). 13C NMR (100.6 MHz, CDCl3) δ 14.5 (q); 30.1 (t); 55.1 (t); 56.3 
(q); 60.6 (d); 67.1 (t); 110.6 (d); 114.1 (d); 117.6 (d); 121.0 (d); 128.3 (s) 134.7 (s); 146.7 (s); 
147.8 (s); 172.0 (s). HRMS m/z calcd. for C15H20NO4 278.1387, found 278.1387. 
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